Where We Stand: AMCP believes that a health care delivery system that is based upon a competitive marketplace will provide greater value to patients and payers than a system that is one‐size‐fits‐all that relies on centralized governmental controls and regulatory mandates.
Where We Stand: AMCP believes that to provide the greatest value to Americans who need prescription drugs, market forces must effectively ensure that manufacturers of similar drugs compete with one another to establish reasonable pricing levels and maintain consumer access to needed therapies.
On July 28, AMCP signed a Medicare Part D stakeholder letter urging HHS to extend the Enhanced Medication Therapy Management (EMTM) Model which is currently set to expire on December 31, 2021.
Medicare Part B pharmaceutical spending has increased rapidly, more than doubling in 2006-2017. Yet, it is unclear whether this increase was driven by increased utilization or increased cost per claim.
Partnership Forum: Participants considered the possible solutions for addressing rising costs and discussed challenges, practical steps for implementing point of sale rebates and other proposed solutions, and discussed how patient assistance programs and copay policies fit into the affordability equation. This forum will develop recommendations and possible solutions to improve price transparency, address the rising costs of medications, and help patient understand and manage drug cost.
Where We Stand: AMCP is concerned that certain cost‐share offset programs may undermine formulary development and utilization management techniques and can also increase costs for health plans and, ultimately, patients themselves.
